Rituximab Therapy for the Patients With HTLV-1-associated Myelopathy

Trial Information
Who is this study for? Patients with Multiple System Atrophy
What treatments are being studied? Rituximab
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
Summary

Neuroprotective or anti-inflammatory strategies are invaluable in HTLV-1-associated myelopathy due to its rapid progression. We evaluated the efficacy of rituximab in patients with HTLV-1-associated myelopathy.

Am I eligible for this trial?
Participation Requirements
Sex:
All
Minimum Age:
18
Maximum Age:
80
Healthy Volunteers:
No

• Age 18-80 years

• Patients HTLV-1-associated myelopathy (tropical spastic paraparesis)

Where is this trial taking place?
Other Locations
China
Department of Neurology ,First Affiliated Hospital Fujian Medical University
Recruiting
Fuzhou
When is this trial taking place?
Start Date: August 15, 2019
Estimated Completion Date: July 2024
How many participants will be in this trial?
Target number of participants: 100
What treatment is being studied in this trial?
Experimental: Rituximab group
Rituximab will be administered as 100 mg IV, once per week for 3 consecutive weeks. Continued dosage was dependent on the percentage of circulating CD19 B-cell counts from patients . Whenever it reached 1% of total lymphocyte population, rituximab 100 mg was reinfused
No Intervention: Control group
Patients will receive usual care and drug use.
Who are the authors of this trial?
Wan-Jian Chen
What other conditions are being studied in this trial?

This content was sourced from clinicaltrials.gov